Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.07
Bid: 2.00
Ask: 2.07
Change: -0.09 (-4.24%)
Spread: 0.07 (3.50%)
Open: 2.20
High: 2.20
Low: 2.07
Prev. Close: 2.125
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of LupuzorT Pivotal Phase III Study

18 Jan 2018 07:00

RNS Number : 2020C
Immupharma PLC
18 January 2018
 

18 JANUARY 2018

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

Completion of Lupuzorâ„¢ Pivotal Phase III Study and Initiation of Follow Up Study

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that the ongoing 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzorâ„¢, its lead programme for the potential breakthrough compound for Lupus, is now complete, following the last patient having attended their final assessment.

Final patient data from the trial are being collated and entered into the database, checked and analysed. This process is ongoing and top line results remain on track to be reported by the end of Q1 2018.

At completion, we continue to observe a robust safety profile over the 12 month period of patients' participation in the trial.

Separately, following requests from both Investigators and patients involved in the Phase III study, ImmuPharma is initiating a "follow-up" study permitting eligible patients from the completed Phase III study, to receive Lupuzorâ„¢ (plus "Standard of Care") for a further six months in an open-label scheme. The results will be gathered as an "extension" open label study, independent of the pivotal Phase III trial which is now completed.

Commenting on the trial update, Robert Zimmer (MD, PhD), President & CSO said: "We are delighted to announce this major milestone for ImmuPharma in having completed on track this pivotal Phase III trial for Lupuzor™.

"I would like to take this opportunity of thanking all of our Clinical Investigators; Simbec-Orion, our clinical research organisation and the ImmuPharma France team led by Dr Fanny Valleix, Head of Clinical Research. All were paramount in the execution and completion of this trial.

"With the continued robust safety achieved over this trial, we look forward with continued confidence to reporting top line results of the study this Q1 2018."

For more information on the trial please visit: https://clinicaltrials.gov/ct2/show/NCT02504645

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.com)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

 

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

 

 

Northland Capital Partners Limited

David Hignell, Jamie Spotswood, Corporate Finance

Rob Rees, Corporate Broking

 

 

+44 (0)20 3861 6625

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESBRMJTMBJBTBP
Date   Source Headline
16th Oct 20173:29 pmRNSHolding(s) in Company
4th Oct 20177:00 amRNSCompletion of Lanstead Sharing Agreement
27th Sep 20177:00 amRNSInterim Results
26th Sep 20177:00 amRNSPreparation of Lupuzor'sT Regulatory Submissions
21st Sep 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
19th Sep 20177:00 amRNSNotification of Interim Results
18th Aug 20175:09 pmRNSAIM Rule 17 Notice
12th Jul 201711:00 amRNSGrant of Options
30th Jun 201712:04 pmRNSResult of AGM
30th Jun 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
7th Jun 20177:00 amRNSAnnual Report & Notice of AGM
1st Jun 20177:00 amRNSFinal Results
22nd May 20177:00 amRNSNotification of Full Year Results
17th May 20177:00 amRNSUpdate on Lupuzor Phase III Study
31st Mar 201710:17 amRNSNew Employee Share Option Plan & Grant of Options
31st Mar 20178:33 amRNSNew Employee Share Option Plan & Grant of Options
24th Mar 20177:00 amRNSImmuPharma to present at Master Investor Show
22nd Mar 20178:51 amRNSHolding(s) in Company
20th Mar 201711:41 amRNSHolding(s) in Company
20th Mar 20177:00 amRNSHolding(s) in Company
10th Mar 20173:52 pmRNS£4.1 Million Fund Raise via Accelerated Bookbuild
10th Mar 20177:00 amRNSAccelerated Bookbuild for the Issue of Equity
6th Mar 20173:55 pmRNSHolding(s) in Company
17th Feb 20172:04 pmRNSHolding(s) in Company
25th Jan 20177:00 amRNSUpdate on Lupuzor Phase III Study
24th Jan 20177:00 amRNSChange of Adviser
29th Dec 201610:54 amRNSHolding(s) in Company
22nd Dec 20167:00 amRNSUpdate on Lupuzor Pivotal Phase III Study
16th Nov 20167:00 amRNSUpdate on Cancer Compound IPP-204106 'Nucant'
9th Nov 20167:00 amRNSHolding(s) in Company
26th Oct 20163:42 pmRNSHolding(s) in Company
21st Oct 20165:13 pmRNSClose of Accelerated Bookbuild
21st Oct 20161:33 pmRNSProposed Accelerated Bookbuild for Vendor Placing
30th Sep 20167:00 amRNSHalf-year Report
14th Sep 20167:00 amRNSUPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
7th Sep 20167:00 amRNSUPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
21st Jul 20168:32 amRNSHolding(s) in Company
1st Jul 20163:52 pmRNSHolding(s) in Company
27th Jun 20164:41 pmRNSSecond Price Monitoring Extn
27th Jun 20164:35 pmRNSPrice Monitoring Extension
20th Jun 20167:00 amRNSAppointment of Joint Broker
9th Jun 20165:56 pmRNSHolding(s) in Company
8th Jun 20167:00 amRNSSymposium with Lupuzors Inventor Prof. S Muller
7th Jun 20167:00 amRNSEuropean Patients Commence Dosing in Lupuzor
2nd Jun 20165:26 pmRNSDirector/PDMR Shareholding
31st May 201610:38 amRNSHolding(s) in Company
26th May 20162:00 pmRNSResult of AGM
25th May 20167:00 amRNSHolding(s) in Company
4th May 20167:01 amRNSAnnual Financial Report & Notice of AGM
4th May 20167:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.